Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT00382161

Improvement of Erectile Dysfunction by Fluvastatin in Patients With Cardiovascular Risk Factors

Influence of Treatment With the HMG-CoA-Reductase Inhibitor Fluvastatin on Erectile Function in Patients With Cardiovascular Risk-Factors and Erectile Dysfunction

Status
Withdrawn
Phase
Phase 3
Study type
Interventional
Enrollment
20 (estimated)
Sponsor
University Hospital, Saarland · Academic / Other
Sex
Male
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of the study is to determine the effect of fluvastatin on penile arterial blood flow and erectile function in patients with arteriogenic ED and cardiovascular risk factors.

Detailed description

Physiology of erection is mainly dependent on endothelial NO-production with consecutive activation of guanylate-cyclase. Pleiotropic effects of statins are well known regarding the increase of endothelial function. Thus, activation of endothelial NO-synthase could raise the activation of guanylate-cyclase with a consecutive relaxation of smooth muscle cells in the penile arteries and the corpus cavernosum leading to an improvement of erectile function. Therefore, statins are supposed to be effective in the treatment of erectile dysfunction, especially in patients with cardiovascular risk-factors with underlying endothelial dysfunction. The effect of fluvastatin on penile blood-flow and erectile function in patients with arteriogenic erectile dysfunction and cardiovascular risk factors will be determined in a cross-over design. Patients were either treated with fluvastatin-sodium 80mg or placebo for 8 weeks. After a wash-out of 4 weeks, treatment will be switched (placebo / fluvastatin-sodium). Penile blood flow measurement and assessment of erectile function with the IIEF-5-score and the KEED-score will be performed at baseline, after 8 weeks of treatment, after 4 weeks wash-out and after cross-over treatment (8 weeks).

Conditions

Interventions

TypeNameDescription
DRUGFluvastatin-sodium

Timeline

Start date
2006-10-01
Completion
2007-12-01
First posted
2006-09-28
Last updated
2009-02-13

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT00382161. Inclusion in this directory is not an endorsement.

Improvement of Erectile Dysfunction by Fluvastatin in Patients With Cardiovascular Risk Factors (NCT00382161) · Clinical Trials Directory